FDA Breakthrough Devices and Human Factors: A Critical Pairing

When the FDA granted Breakthrough Device designation to ReVision Implant's Occular visual cortical prosthesis last week, the Belgian neurotechnology startup joined an accelerated pathway designed to fast-track transformative medical technologies. But here's the critical detail that often gets lost in the celebration: breakthrough designation doesn't exempt you from rigorous human factors engineering, it intensifies the scrutiny. As Staci Miller from GenUX recently explained in a discussion with Greenlight Guru, treating human factors as a late-stage compliance checkbox is precisely why many high-innovation submissions stall or fail, even with breakthrough status. These two stories illuminate a fundamental tension in modern medical device development: the faster you want to move, the earlier you need to embed HFE into your design process.
Why Breakthrough Designation Demands Better Human Factors, Not Less
ReVision Implant's Occular system represents the kind of technology breakthrough designation was created for: a visual cortical prosthesis that could restore functional vision to patients with severe blindness, including those whose conditions can't be addressed through retinal interventions. This is Class III territory, high-risk, life-altering technology implanted directly into the brain. The breakthrough pathway offers benefits like priority review, interactive communication with FDA, and potential for expedited market authorisation. But it doesn't lower the bar for demonstrating safe and effective use.
In fact, the opposite is true. Breakthrough devices often involve novel user interfaces, complex implantation procedures, and patient populations with limited treatment alternatives. The FDA's expectations for human factors validation become more stringent, not less. You're not just proving your device works, you're proving that surgeons can implant it correctly under realistic conditions, that patients or caregivers can operate it safely in actual home environments, and that use errors won't compromise the benefits that earned you breakthrough status in the first place.
This is where Staci Miller's insights become critical. She emphasises that many manufacturers fundamentally misunderstand the role of HFE in the regulatory pathway. They treat it as documentation to be generated after design freeze, rather than as an iterative design input that should shape the device from concept phase forward. The result? Formative studies conducted too late to influence design, summative validation studies that reveal critical use errors when tooling is already committed, and submissions that tell disconnected stories between clinical evidence and real-world usability.
The Box-Checking Trap: Why Submissions Stall Despite Strong Clinical Data
Miller identifies a pattern that regulatory affairs professionals will recognise immediately: companies arrive at submission with robust clinical trial data proving safety and efficacy, but their human factors documentation is thin, retrospective, or disconnected from actual device design decisions. The FDA reviewer sees a device that works in controlled clinical settings but lacks credible evidence it will be used correctly in the real world. The submission stalls.
This isn't about the FDA being difficult. It reflects a legitimate regulatory concern, particularly for breakthrough devices where there's no predicate device to reference and no established user expectations. Consider the Occular system: surgeons will need training on cortical implantation techniques that don't exist in current practice. Patients will interact with external components of a system that interprets their intention to see and translates it into neural stimulation patterns. Every interface, every control, every feedback mechanism is a potential point of use error that could undermine the therapy or cause patient harm.
The companies that succeed in breakthrough pathways understand that human factors engineering and clinical development must proceed in parallel, informing each other iteratively. Formative HFE studies identify use risks early enough to redesign interfaces. Simulated use testing validates that risk controls actually work before you commit to final design. Summative validation becomes a confirmation exercise rather than a high-stakes discovery process. The documentation tells a coherent story: here's how we identified use-related risks, here's how we designed them out or mitigated them, and here's the evidence that our approach works with representative users in realistic conditions.
What This Means for Your Team: Integration Points That Actually Matter
If you're pursuing breakthrough designation, or any accelerated pathway for that matter, your regulatory strategy needs to integrate human factors engineering from day one. This isn't about hiring an HF consultant to write a report before submission. It's about embedding HFE principles into your design controls, risk management, and clinical strategy.
Start with your use specification and user research before your first prototype. Who are your actual users, not just the intended patient population but everyone who interacts with the device? What's their training level, their physical and cognitive capabilities, their use environment? For a device like Occular, this means mapping the neurosurgeon's workflow in the operating theatre, the patient's daily interaction with external components, and potentially a caregiver's role in system maintenance or troubleshooting. These insights should drive design requirements, not validate decisions already made.
Integrate HFE into your risk management process under ISO 14971. Use-related risks should appear in your risk analysis alongside technical and biological hazards. Your design risk controls should be validated through HFE methods, formative testing with representative users, not just engineering verification. When you conduct clinical trials, think about how those protocols can also generate human factors evidence. Can you collect data on use errors, near misses, or challenging use scenarios? Can you validate training materials and user interfaces in the clinical setting?
For regulatory affairs professionals, this means your submission strategy should map the human factors story alongside the clinical narrative. Your FDA Pre-Submission meetings should include discussion of your HFE approach, not just clinical trial design. Your breakthrough device designation application should articulate how you'll address use-related risks for a novel therapy. When you draft your submission, the human factors section shouldn't read like an afterthought, it should demonstrate that usability and safety were design priorities from the beginning.
The ARPA-H Signal: Complexity is Coming to Wearables Too
It's worth noting briefly that ARPA-H's new programme to develop biosensors that track multiple signals simultaneously points to another area where this HFE-breakthrough device intersection will become critical. As wearables grow more sophisticated, measuring multiple physiological parameters and making complex health determinations, they'll increasingly seek breakthrough or De Novo pathways. The same human factors challenges apply: more data doesn't help patients if the interface is confusing, if alerts cause alarm fatigue, or if users can't understand what action to take based on sensor readings. The lesson from ReVision's breakthrough designation applies across the innovation spectrum: the more novel your technology, the earlier you need to think about how humans will actually use it.
Key Takeaways
- Breakthrough Device designation accelerates review timelines but intensifies scrutiny of human factors engineering, particularly for novel devices without predicates
- Treating HFE as a late-stage documentation exercise leads to submission delays even when clinical data is strong, because FDA needs credible evidence of safe use in real-world conditions
- Successful breakthrough submissions integrate HFE and clinical development in parallel: formative studies inform design decisions, risk controls are validated through simulated use, and summative studies confirm rather than discover use-related risks
- Regulatory strategy should embed HFE from Pre-Submission stage forward: discuss your approach with FDA early, map human factors evidence alongside clinical narratives, and ensure your submission tells a coherent story about how design decisions addressed use-related risks
- As medical devices grow more complex, from cortical prostheses to multi-parameter biosensors, the integration of HFE into early design and regulatory planning becomes a competitive advantage, not just a compliance requirement
The breakthrough pathway exists to accelerate access to transformative therapies, but speed without rigorous attention to human factors creates risk for patients, manufacturers, and the credibility of the accelerated pathway itself. ReVision Implant's achievement with Occular is significant, and the team's success in bringing this technology through clinical trials will depend substantially on how thoroughly they've integrated human factors engineering into every stage of development. For regulatory affairs teams navigating EU MDR, FDA breakthrough designations, or MHRA innovation pathways, the message is clear: innovative technology and rigorous HFE aren't competing priorities, they're inseparable requirements. The teams that understand this early are the ones whose submissions move forward while others stall at the gate.